张鸿声.嵌合抗原受体T细胞肿瘤治疗的前生、今世和将来[J].转化医学杂志,2014,3(3):129-133
嵌合抗原受体T细胞肿瘤治疗的前生、今世和将来
Past history, present status and future prospect of cancer immunotherapy adopting chimeric antigen receptor T lymphocytes
  
DOI:
中文关键词:  嵌合抗原受体  T细胞  肿瘤  免疫细胞治疗
英文关键词:Chimeric antigen receptor(CAR)  T cell  Tumor  Immune therapy
基金项目:国家自然科学基金(81272325);上海市浦江人才计划(12PJ1433700)
作者单位
张鸿声 同济大学医学院附属上海肺科医院转化医学中心 
摘要点击次数: 2702
全文下载次数: 5025
中文摘要:
      嵌合抗原受体修饰的T细胞在B淋巴细胞性白血病的治疗上已经取得突破性进展。近来,美国的几个临床研究中心报道了在这群患者中取得高达60%~80%临床反应率的良好疗效。这一振奋人心的结果带来了人们对免疫治疗新的热情和随之而来的大型制药公司和投资机构对这一领域的关注。免疫治疗需要在加强有效性的基础上,发展出更多的免疫治疗方法以增加这一治疗的多样性,才会对癌症这一对人类健康具有重大挑战的疾病产生真正的影响。我们相信随着转化医学研究的不断深入,21世纪将是免疫治疗走向癌症治疗中心舞台的时代。
英文摘要:
      Clinical trials adopting chimeric antigen receptor T lymphocytes (CAR T) have made a breakthrough in treatment of B lymphocytic leukemia. Several clinical research centers in USA have reported excellent clinical response rate of 60%—80% in these group of patients. This in turn drives a new wave of enthusiasm in immunotherapy, and comes along with interests and investment from big pharmaceutical companies,as well as investment firms. In order for immunotherapy to make a major impact in cancer therapy, it is required not only to enhance its effectiveness, but also to increase its variety. We believe, with more and more interests in translational medical research, the 21 Century will be an era that immunotherapy enters the center stage of cancer therapy.
查看全文  查看/发表评论  下载PDF阅读器
关闭